Abbott Bids To Toss Antitrust Charges Over TriCor

Law360, New York (March 15, 2006, 12:00 AM EST) -- A persistent legal battle plagues Abbott Laboratories one year after the company resolved a patent dispute with Israeli drug maker Teva Pharmaceutical Industries Ltd., which has accused Abbott of antitrust violations over its blockbuster cholesterol treatment TriCor.

The Chicago-based Abbott asked a federal court this week to dismiss charges brought by Teva, along with Impax Laboratories Inc. and consumers and health plan funders, alleging that Abbott has employed unfair tactics to keep competitors from launching generic versions of TriCor.

The generic drug makers and consumers say...
To view the full article, register now.